Lessons Learned from HERA: the First Alport Syndrome Therapeutic Clinical Trial.
作者信息
Weinstock B André
机构信息
Alport Syndrome Foundation, Scottsdale, Arizona.
出版信息
Clin J Am Soc Nephrol. 2024 Aug 1;19(8):946-948. doi: 10.2215/CJN.0000000000000506. Epub 2024 Jun 21.
Abstract
摘要
相似文献
1
Lessons Learned from HERA: the First Alport Syndrome Therapeutic Clinical Trial.
Clin J Am Soc Nephrol. 2024 Aug 1;19(8):946-948. doi: 10.2215/CJN.0000000000000506. Epub 2024 Jun 21.
2
Familial hematurias: what we know and what we don't.
Pediatr Nephrol. 2005 Aug;20(8):1027-35. doi: 10.1007/s00467-005-1859-z. Epub 2005 Apr 27.
3
Could This Be Alport Syndrome?
Clin J Am Soc Nephrol. 2021 Nov;16(11):1743-1745. doi: 10.2215/CJN.00120121. Epub 2021 Apr 13.
4
Outcome of females with Alport syndrome.
Pediatr Nephrol. 2022 Aug;37(8):1937. doi: 10.1007/s00467-022-05592-4. Epub 2022 Apr 27.
5
[Research progress in diagnosis, treatment and management of Alport syndrome].
Zhonghua Er Ke Za Zhi. 2022 Apr 2;60(4):370-373. doi: 10.3760/cma.j.cn112140-20210907-00759.
6
Guidelines for Genetic Testing and Management of Alport Syndrome.
Clin J Am Soc Nephrol. 2022 Jan;17(1):143-154. doi: 10.2215/CJN.04230321. Epub 2021 Dec 20.
7
Clinical utility gene card for: Alport syndrome.
Eur J Hum Genet. 2012 Jun;20(6). doi: 10.1038/ejhg.2011.237. Epub 2011 Dec 14.
8
[Precision diagnosis and therapeutic intervention of Alport syndrome].
Zhonghua Yi Xue Za Zhi. 2024 Apr 23;104(16):1347-1350. doi: 10.3760/cma.j.cn112137-20231010-00690.
9
[Alport syndrome: Pathogenesis, pathophysiology, and therapy].
Nihon Rinsho. 2006 Feb;64 Suppl 2:531-6.
10
Genetic testing and glomerular hematuria-A nephrologist's perspective.
Am J Med Genet C Semin Med Genet. 2022 Sep;190(3):399-403. doi: 10.1002/ajmg.c.31987. Epub 2022 Jul 1.
本文引用的文献
1
A Randomized Controlled Clinical Trial Testing Effects of Lademirsen on Kidney Function Decline in Adults with Alport Syndrome.
Clin J Am Soc Nephrol. 2024 Aug 1;19(8):995-1004. doi: 10.2215/CJN.0000000000000458. Epub 2024 Jun 3.
2
Polygenic risk alters the penetrance of monogenic kidney disease.
Nat Commun. 2023 Dec 14;14(1):8318. doi: 10.1038/s41467-023-43878-9.
3
Prevalence Estimates of Predicted Pathogenic Variants in a Population Sequencing Database and Their Implications for Alport Syndrome.
J Am Soc Nephrol. 2021 Sep;32(9):2273-2290. doi: 10.1681/ASN.2020071065. Epub 2021 Jun 18.
4
Isotopic Nitrogen-15 Labeling of Mice Identified Long-lived Proteins of the Renal Basement Membranes.
Sci Rep. 2020 Mar 24;10(1):5317. doi: 10.1038/s41598-020-62348-6.
5
Diagnostic Utility of Exome Sequencing for Kidney Disease.
N Engl J Med. 2019 Jan 10;380(2):142-151. doi: 10.1056/NEJMoa1806891. Epub 2018 Dec 26.
6
Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group.
Kidney Int. 2018 May;93(5):1045-1051. doi: 10.1016/j.kint.2017.12.018. Epub 2018 Mar 16.
7
Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome.
Genes Dev. 1996 Dec 1;10(23):2981-92. doi: 10.1101/gad.10.23.2981.
Zotero 插件